ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: 0959 • ACR Convergence 2024

    Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease

    David Lauer1, Matthias Brunner2, Hubert Gabrys3, Kerstin Klein2, Oliver Distler4, Britta Maurer5 and Janine Gote-Schniering2, 1University Hospital Bern, Bern, Switzerland, 2University of Bern, Bern, Switzerland, 3University Hospital Zurich, Zurich, Zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 5University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
  • Abstract Number: 0959 • ACR Convergence 2023

    Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis

    Heetaek Yang1, Rajan Bhandari1, Saemi Han2, Chanhyuk Park1, Chen-Yu Wang2, Emily Morris1, Michael Whitfield1 and Patricia Pioli1, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Dartmouth College, Hanover, NH

    Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease with multiple clinical and pathological manifestations including vascular involvement, immune activation, oxidative stress, and fibrosis. In…
  • Abstract Number: 0959 • ACR Convergence 2022

    Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data

    Amadeia Rector1, Ivana Marić2, Yashaar Chaichian3, Eliza Chakravarty4, Miranda Cantu5, Michael Weisman6, Gary Shaw7, Maurice Druzin7 and Julia Simard1, 1Stanford University School of Medicine, Palo Alto, CA, 2Stanford University, Stanford, 3Stanford University, Stanford, CA, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Global Lupus Support Group, Portage, MI, 6Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 7Stanford University School of Medicine, Palo Alto

    Background/Purpose: Preeclampsia risk is higher among pregnancies in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ), a common first-line treatment, is encouraged in SLE pregnancies…
  • Abstract Number: 0959 • ACR Convergence 2021

    Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort

    Celline Brasil1, John Hanly2, Murray Urowitz3, Ann Clarke4, Rosalind Ramsey-Goldman5, Caroline Gordon6, Michelle Petri7, Ellen Ginzler8, Daniel Wallace9, Sang-Cheol Bae10, Juanita Romero-Diaz11, Mary Anne Dooley12, Christine Peschken13, David Isenberg14, Anisur Rahman15, Susan Manzi16, Soren Jacobsen17, S Sam Lim18, Ronald F van Vollenhoven19, Ola Nived20, Andreas Jnsen20, Diane Kamen21, Cynthia Aranow22, Guillermo Ruiz-Irastorza23, Jorge Sanchez-Guerrero24, Dafna Gladman25, Paul R Fortin26, Graciela Alarcn27, Joan Merrill28, Kenneth Kalunian29, Manuel Ramos-Casals30, Kristjan Steinsson31, Asad Zoma32, Anca Askanase33, Munther Khamashta34, Ian N. Bruce35, Murat Inanc36 and Sasha Bernatsky37, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2Dalhousie University, Halifax, NS, Canada, 3Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 4University of Calgary, Calgary, AB, Canada, 5Northwestern University, Chicago, IL, 6Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8SUNY Downstate Health Sciences University, Brooklyn, NY, 9Cedars-Sinai, Los Angeles, CA, 10Hanyang University Medical Center, Seoul, Republic of Korea, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, 12Raleigh Neurology Associates, Chapel Hill, NC, 13University of Manitoba, Winnipeg, MB, Canada, 14Centre for Rheumatology, University College London, London, United Kingdom, 15University College London, London, United Kingdom, 16Allegheny Health Network, Wexford, PA, 17Rigshospitalet, Copenhagen, Denmark, 18Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 19Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 20Lund University, Lund, Sweden, 21Medical University of South Carolina, Charleston, SC, 22Feinstein Institutes for Medical Research, Manhasset, NY, 23Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, 24University Health Network, Toronto, ON, Canada, 25Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 26CHU de Quebec - Universite Laval, Québec City, QC, Canada, 27University of Alabama at Birmingham, Birmingham, AL, 28Oklahoma Medical Research Foundation, Oklahoma City, OK, 29UC San Diego, La Jolla, CA, 30Hospital Clinic, Barcelona, Barcelona, Spain, 31National University Hospital of Iceland, Reykjavik, Iceland, 32University of Glasgow, East Kilbride, United Kingdom, 33Columbia University Medical Center, New York, NY, 34King's College London, London, United Kingdom, 35University of Manchester, Manchester, United Kingdom, 36Istanbul University Faculty of Medicine, Istanbul, Turkey, 37McGill University, Montréal, QC, Canada

    Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…
  • Abstract Number: 0959 • ACR Convergence 2020

    Altered Gut Microbiome in Dermatomyositis

    Sangmee Bae1, Tien Dong2, Venu Lagishetty3, William Katzka4, Jonathan Jacobs3 and Christina Charles-Schoeman5, 1University of California Los Angeles, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, 3University of California, Los Angeles, Los Angeles, 4UCLA, Los Angeles, 5University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy associated with marked microvascular dysfunction and high morbidity and mortality. The gut microbiome has been implicated in the…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology